Corante

About this Author
DBL%20Hendrix%20small.png College chemistry, 1983

Derek Lowe The 2002 Model

Dbl%20new%20portrait%20B%26W.png After 10 years of blogging. . .

Derek Lowe, an Arkansan by birth, got his BA from Hendrix College and his PhD in organic chemistry from Duke before spending time in Germany on a Humboldt Fellowship on his post-doc. He's worked for several major pharmaceutical companies since 1989 on drug discovery projects against schizophrenia, Alzheimer's, diabetes, osteoporosis and other diseases. To contact Derek email him directly: derekb.lowe@gmail.com Twitter: Dereklowe

Chemistry and Drug Data: Drugbank
Emolecules
ChemSpider
Chempedia Lab
Synthetic Pages
Organic Chemistry Portal
PubChem
Not Voodoo
DailyMed
Druglib
Clinicaltrials.gov

Chemistry and Pharma Blogs:
Org Prep Daily
The Haystack
Kilomentor
A New Merck, Reviewed
Liberal Arts Chemistry
Electron Pusher
All Things Metathesis
C&E News Blogs
Chemiotics II
Chemical Space
Noel O'Blog
In Vivo Blog
Terra Sigilatta
BBSRC/Douglas Kell
ChemBark
Realizations in Biostatistics
Chemjobber
Pharmalot
ChemSpider Blog
Pharmagossip
Med-Chemist
Organic Chem - Education & Industry
Pharma Strategy Blog
No Name No Slogan
Practical Fragments
SimBioSys
The Curious Wavefunction
Natural Product Man
Fragment Literature
Chemistry World Blog
Synthetic Nature
Chemistry Blog
Synthesizing Ideas
Business|Bytes|Genes|Molecules
Eye on FDA
Chemical Forums
Depth-First
Symyx Blog
Sceptical Chymist
Lamentations on Chemistry
Computational Organic Chemistry
Mining Drugs
Henry Rzepa


Science Blogs and News:
Bad Science
The Loom
Uncertain Principles
Fierce Biotech
Blogs for Industry
Omics! Omics!
Young Female Scientist
Notional Slurry
Nobel Intent
SciTech Daily
Science Blog
FuturePundit
Aetiology
Gene Expression (I)
Gene Expression (II)
Sciencebase
Pharyngula
Adventures in Ethics and Science
Transterrestrial Musings
Slashdot Science
Cosmic Variance
Biology News Net


Medical Blogs
DB's Medical Rants
Science-Based Medicine
GruntDoc
Respectful Insolence
Diabetes Mine


Economics and Business
Marginal Revolution
The Volokh Conspiracy
Knowledge Problem


Politics / Current Events
Virginia Postrel
Instapundit
Belmont Club
Mickey Kaus


Belles Lettres
Uncouth Reflections
Arts and Letters Daily
In the Pipeline: Don't miss Derek Lowe's excellent commentary on drug discovery and the pharma industry in general at In the Pipeline

In the Pipeline

« Joy | Main | Know How to Make Praziquantel? Tell The World. »

August 2, 2010

Charles River Gives Up

Email This Entry

Posted by Derek

So when Charles River Laboratories announced that it was buying WuXi, its stock dropped pretty sharply. But unlike many other takeovers, it never recovered, and a lot of the company's shareholders seem to have continued to be unhappy about the deal.

Unhappy enough so that on Friday the whole thing was called off. As that article makes clear, this is being seen as a particular victory for Jana, a hedge fund that's the largest single Charles River shareholder.

So where does this leave Charles River? Announcing a stock buyback plan and thinking about what the heck to do next. And where does it leave WuXi? That's a tough one, too. Someone else may decide to buy them (someone for whom it won't be as much of a stretch (and as hard a sell for the investors). But the price probably won't be as good this time around, at least not if an attempted deal happens in the near future. Or they may decide that it's time that they try to become the First Great Chinese Pharma Company. It's going to be a while before anything's clear - other than the fact that this particular deal isn't going through, that is. . .

Comments (11) + TrackBacks (0) | Category: Business and Markets


COMMENTS

1. darwin on August 2, 2010 1:44 PM writes...

where should i start?...

Permalink to Comment

2. anonymous coward on August 2, 2010 4:05 PM writes...

Perhaps CEO Foster will finally have time to explain why he believes the Chinese at WuXi are better educated than American researchers.

My guess is that it's because America's best and brightest have opted to work at hedge funds like Jana. It explains both Foster's previous comments and the fact that this bone-headed merger didn't go through.

Permalink to Comment

3. hell to the chief on August 2, 2010 6:00 PM writes...

Everything CR does now will go the same way as first early stage chemistry and then medicinal chemistry, PK, GLP bioanalytical etc. have gone. CR knew this and were trying to head it off but unfortunately for them, a hedge fund thought they knew better. Within 3-5 years all the GLP, IND-enabling and later stage studies that CR do or supply animals for will all be done in the WuXi Souzhou facitlity and WuXi will be in a position to take over CR rather than the reverse.

Permalink to Comment

4. processchemist on August 3, 2010 2:57 AM writes...

Imho #3 is right. Probably Jana guys know that chinese CRO generate profits until they remain chinese. And this has nothing to do with discovering new drugs.

Permalink to Comment

5. A Nonny Mouse on August 3, 2010 2:59 AM writes...

An associate of mine has just returned from China having set up a company to do all of the pre-clinical, P1 and P2 studies, with facilities being supplied FOC by the Chinese government. How can CR hope to compete with this?

Permalink to Comment

6. processchemist on August 3, 2010 4:03 AM writes...

@5

This is usually called "dumping". Considering the few actions taken about dumping on products, probably any kind of battle against dumping on services has no hope at all. And this while the Chinese government makes more difficult china *importations*.
And many people in the western world still talk about the advantages of a global *free* market.
It's fun to play poker by the rules when the winning player is allowed to use some spare aces?

Permalink to Comment

7. Anonymous on August 3, 2010 4:45 AM writes...

I think one day soon WuXi will buy CharlesRiver and others also...

China will take over...

Permalink to Comment

8. MTK on August 3, 2010 7:09 AM writes...

Interesting that the stock took a big nosedive on the announcement of the buy on Apr 26, bounced around for awhile, then basically climbed up as the broader market fell, then started diving again last Thursday. 13% since opening on Thursday. Clearly word had gotten out a day before the announcement that CRL was giving up. So it seems that some of the shareholders at least were bullish on the merger.

Jana's stance on this is puzzling. They bought 7% of the company's stock after the WuXi purchase was announced! Then they pull the plug on it? Clearly, they didn't buy based on long-term value of the deal. Almost seems like they bought CRL on the cheap, knew they could torpedo the deal, and believed that the stock would go back to pre-deal values, thus making a handsome profit.

Didn't quite work that way now has it.

Permalink to Comment

9. Anonymous on August 4, 2010 9:04 PM writes...

It reminds me of high school when choosing your date for the prom. If something goes wrong, you're toast and damaged goods! Glad i didn't attend my prom.

Permalink to Comment

10. Anonymous on August 9, 2010 2:28 PM writes...

State of the art labs, plenty of man power working 24/7. Wuxi is a force to be reckoned with to be sure.

Permalink to Comment

11. anon on August 9, 2010 8:03 PM writes...

"And many people in the western world still talk about the advantages of a global *free* market."

The "free market" is total bullcr*p when dealing with police states that use prison labor and dump all their waste in their rivers. It's a fairy tale told told by the rich to us peons to keep us believing we can somehow get on the exclusive gravy train. About as likely as getting a date with Paris Hilton.

Permalink to Comment

POST A COMMENT




Remember Me?



EMAIL THIS ENTRY TO A FRIEND

Email this entry to:

Your email address:

Message (optional):




RELATED ENTRIES
How Not to Do It: NMR Magnets
Allergan Escapes Valeant
Vytorin Actually Works
Fatalities at DuPont
The New York TImes on Drug Discovery
How Are Things at Princeton?
Phage-Derived Catalysts
Our Most Snorted-At Papers This Month. . .